Drug Profile
Research programme: MAP4K4 inhibitors - Imperial College of Science, Technology and Medicine/ Domainex
Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Imperial College of Science, Technology and Medicine
- Developer Domainex; Imperial College of Science, Technology and Medicine
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Myocardial-infarction in United Kingdom
- 07 Mar 2019 Preclinical trials in Myocardial infarction in United Kingdom (unspecified route) before March 2019
- 07 Mar 2019 Domainex plans a clinical trial for Myocardial infarction in 2021-2022